Cartesian Therapeutics, Inc. Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale
Cartesian Therapeutics, Inc. (RNAC) reported Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale of $0 for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale · last filed 2022-08-08
- Cartesian Therapeutics, Inc. other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2022-06-30 was $0.00.
- Cartesian Therapeutics, Inc. other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2022-03-31 was $0.00.
- Cartesian Therapeutics, Inc. other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2021-12-31 was $0.00.
- Cartesian Therapeutics, Inc. other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2021-09-30 was $0.00.
- Cartesian Therapeutics, Inc. other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2021 was $0.00.
| Period end | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 3 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 6 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 9 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $0.00 10-Q · filed 2022-08-08 | $0.00 derived: sum of 3 quarters · filed 2022-08-08 | $0.00 derived: sum of 4 quarters · filed 2022-08-08 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 | $0.00 derived: sum of 2 quarters · filed 2022-05-05 | $0.00 derived: sum of 3 quarters · filed 2022-05-05 | $0.00 derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $0.00 derived: sum of 2 quarters · filed 2022-03-10 | $0.00 derived: sum of 3 quarters · filed 2022-03-10 | $0.00 10-K · filed 2022-03-10 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |